Afficher la notice abrégée

Differential cardiovascular impacts of sodium salts: unveiling the distinct roles of sodium chloride and sodium bicarbonate-consequences for heart failure patients.

dc.rights.licenseopenen_US
dc.contributor.authorSADKI, Dalil
dc.contributor.authorFAWAZ, Sami
dc.contributor.authorLIEGEY, Jean-Sebastien
dc.contributor.authorPUCHEU, Yann
dc.contributor.authorBOULESTREAU, Romain
dc.contributor.authorBEUQUE, Gauthier
dc.contributor.authorFOUCHER, Jeanne
dc.contributor.authorHEIN, Louise
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorCOUFFINHAL, Thierry
dc.date.accessioned2025-03-04T14:03:20Z
dc.date.available2025-03-04T14:03:20Z
dc.date.issued2025-02-24
dc.identifier.issn2047-4881en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205350
dc.description.abstractEnMisconceptions surrounding sodium compounds, particularly the interchangeable use of sodium and sodium chloride (table salt), persist within the medical community, influencing dietary recommendations and patient management especially in heart failure (HF) patients with chronic kidney disease (CKD). This narrative review aims to dissect these misconceptions and discusses the physiological impacts of sodium, chloride, and sodium bicarbonate on cardiovascular (CV) physiology. The conflation of sodium and sodium chloride in dietary recommendations has obscured critical differences in their physiological effects. While sodium chloride is traditionally linked to hypertension, emerging evidence suggests that chloride, rather than sodium, may be the primary driver of hypertension and activation of the renin-angiotensin-aldosterone system. In contrast, sodium bicarbonate, when administered orally, seems to exert minimal effects on blood pressure and plasma volume, offering a promising and safe way for managing HF patients with renal insufficiency. Indeed, the therapeutic benefits of sodium bicarbonate in CKD patients, including preservation of muscle mass, slowing of renal function decline, lowering of all-cause mortality, and improved nutritional status, are quite proven; this underscores its potential utility in patients suffering from both HF and renal insufficiency. Despite concerns about metabolic alkalosis, recent studies suggest that judicious sodium bicarbonate therapy may mitigate major adverse cardiac events without exacerbating HF. This review advocates for a paradigm shift in CV medicine, urging clinicians to discern between sodium chloride and other sodium salts, particularly sodium bicarbonate, in patient care. By elucidating these distinctions, clinicians can tailor dietary recommendations and therapeutic interventions to optimize outcomes for HF patients with CKD and address the multi-faceted complexities of atherosclerotic disease. This review clarifies the physiological differences between sodium chloride and sodium bicarbonate, advocating for a nuanced approach in managing cardiovascular (CV) health in patients with heart failure (HF) and chronic kidney disease (CKD). Sodium chloride (table salt) is commonly associated with hypertension, whereas chloride, rather than sodium itself, appears to be the primary factor influencing blood pressure and activation of the renin-angiotensin-aldosterone system.Sodium bicarbonate shows promise in managing CKD by preserving muscle mass, slowing renal decline, reducing all-cause mortality, and improving nutritional status without significantly impacting blood pressure or plasma volume, making it secure in patients with HF. By distinguishing between these sodium compounds, clinicians can better tailor dietary recommendations and treatments to improve outcomes for patients with HF and CKD, advancing the management of CV diseases.
dc.language.isoENen_US
dc.title.enDifferential cardiovascular impacts of sodium salts: unveiling the distinct roles of sodium chloride and sodium bicarbonate-consequences for heart failure patients.
dc.title.alternativeEur J Prev Cardiolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/eurjpc/zwaf020en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed39988808en_US
bordeaux.journalEuropean Journal of Preventive Cardiologyen_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04976274
hal.version1
hal.date.transferred2025-03-04T14:03:23Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Preventive%20Cardiology&rft.date=2025-02-24&rft.eissn=2047-4881&rft.issn=2047-4881&rft.au=SADKI,%20Dalil&FAWAZ,%20Sami&LIEGEY,%20Jean-Sebastien&PUCHEU,%20Yann&BOULESTREAU,%20Romain&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée